Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
ABSTRACT Purpose Our study aimed to comprehensively describe the features of peripheral blood multiple immune cell phenotypes in solid tumor patients during pretreatment and after immunotherapy, providing a more convenient approach for studying the prognosis of immunotherapy in different solid tumor...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15493 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221703335411712 |
|---|---|
| author | Ling Chen Hourui Tan Ruixuan Geng Yifan Li Yingyi Wang Taisheng Li |
| author_facet | Ling Chen Hourui Tan Ruixuan Geng Yifan Li Yingyi Wang Taisheng Li |
| author_sort | Ling Chen |
| collection | DOAJ |
| description | ABSTRACT Purpose Our study aimed to comprehensively describe the features of peripheral blood multiple immune cell phenotypes in solid tumor patients during pretreatment and after immunotherapy, providing a more convenient approach for studying the prognosis of immunotherapy in different solid tumor patients. Methods We prospectively recruited patients with advanced solid tumors from Peking Union Medical College Hospital (PUMCH) between February 2023 and April 2024. Using multicolor flow cytometry, our study comprehensively observed and described the signatures of peripheral blood lymphocyte subsets including activation, proliferation, function, naïve memory, and T cell exhaustion immune cell subsets in this population of pretreatment and after immunotherapy. Results Our study enrolled 59 advanced solid tumor patients with immunotherapy and 59 healthy controls were matched by age and gender. The results demonstrated a marked upregulation in the expression of lymphocyte activation markers CD38 and HLA‐DR, as well as exhaustion and proliferation markers PD‐1 and Ki67, in solid tumor patients compared to healthy controls. After immune checkpoint blockade (ICB) treatment, mainly the expression of Ki67CD4+T and HLA‐DRCD38CD4+T, was significantly upregulated compared to pretreatment levels (p = 0.017, p = 0.019, respectively). We further found that gynecological tumors with better prognoses had higher baseline activation levels of CD4+ T cells compared to other solid tumors with poorer prognoses. Conclusion Our study elucidated the characteristics of different lymphocyte subsets in the peripheral blood of solid tumor patients. Further research revealed changes in the phenotypes of different lymphocyte subsets after ICIs treatment, with the activated phenotype of CD4+ T cells playing a crucial role in the antitumor effect. This lays the groundwork for further exploration of prognostic biomarkers and predictive models for cancer patients with immunotherapy. |
| format | Article |
| id | doaj-art-30413ecb57084b7aabd61c477bd9f7a4 |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-30413ecb57084b7aabd61c477bd9f7a42025-01-15T16:00:32ZengWileyThoracic Cancer1759-77061759-77142025-01-01161n/an/a10.1111/1759-7714.15493Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational StudyLing Chen0Hourui Tan1Ruixuan Geng2Yifan Li3Yingyi Wang4Taisheng Li5Department of Infectious Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaDepartment of Medical Oncology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of International Medical Services Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Gynecologic Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Infectious Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaABSTRACT Purpose Our study aimed to comprehensively describe the features of peripheral blood multiple immune cell phenotypes in solid tumor patients during pretreatment and after immunotherapy, providing a more convenient approach for studying the prognosis of immunotherapy in different solid tumor patients. Methods We prospectively recruited patients with advanced solid tumors from Peking Union Medical College Hospital (PUMCH) between February 2023 and April 2024. Using multicolor flow cytometry, our study comprehensively observed and described the signatures of peripheral blood lymphocyte subsets including activation, proliferation, function, naïve memory, and T cell exhaustion immune cell subsets in this population of pretreatment and after immunotherapy. Results Our study enrolled 59 advanced solid tumor patients with immunotherapy and 59 healthy controls were matched by age and gender. The results demonstrated a marked upregulation in the expression of lymphocyte activation markers CD38 and HLA‐DR, as well as exhaustion and proliferation markers PD‐1 and Ki67, in solid tumor patients compared to healthy controls. After immune checkpoint blockade (ICB) treatment, mainly the expression of Ki67CD4+T and HLA‐DRCD38CD4+T, was significantly upregulated compared to pretreatment levels (p = 0.017, p = 0.019, respectively). We further found that gynecological tumors with better prognoses had higher baseline activation levels of CD4+ T cells compared to other solid tumors with poorer prognoses. Conclusion Our study elucidated the characteristics of different lymphocyte subsets in the peripheral blood of solid tumor patients. Further research revealed changes in the phenotypes of different lymphocyte subsets after ICIs treatment, with the activated phenotype of CD4+ T cells playing a crucial role in the antitumor effect. This lays the groundwork for further exploration of prognostic biomarkers and predictive models for cancer patients with immunotherapy.https://doi.org/10.1111/1759-7714.15493immune checkpoint inhibitorslymphocyte subsetsperipheral bloodsolid tumor |
| spellingShingle | Ling Chen Hourui Tan Ruixuan Geng Yifan Li Yingyi Wang Taisheng Li Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study Thoracic Cancer immune checkpoint inhibitors lymphocyte subsets peripheral blood solid tumor |
| title | Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study |
| title_full | Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study |
| title_fullStr | Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study |
| title_full_unstemmed | Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study |
| title_short | Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study |
| title_sort | immune signatures of solid tumor patients treated with immune checkpoint inhibitors an observational study |
| topic | immune checkpoint inhibitors lymphocyte subsets peripheral blood solid tumor |
| url | https://doi.org/10.1111/1759-7714.15493 |
| work_keys_str_mv | AT lingchen immunesignaturesofsolidtumorpatientstreatedwithimmunecheckpointinhibitorsanobservationalstudy AT houruitan immunesignaturesofsolidtumorpatientstreatedwithimmunecheckpointinhibitorsanobservationalstudy AT ruixuangeng immunesignaturesofsolidtumorpatientstreatedwithimmunecheckpointinhibitorsanobservationalstudy AT yifanli immunesignaturesofsolidtumorpatientstreatedwithimmunecheckpointinhibitorsanobservationalstudy AT yingyiwang immunesignaturesofsolidtumorpatientstreatedwithimmunecheckpointinhibitorsanobservationalstudy AT taishengli immunesignaturesofsolidtumorpatientstreatedwithimmunecheckpointinhibitorsanobservationalstudy |